TradeFlare's AI research teams analysed REPL on 19 market nights between June 2, 2026 and September 24, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 24, 2026 | HOLD | $12.96 | — / — | +6.8% | not yet | The current market regime and stock-specific factors do not support a BUY recommendation. |
| September 22, 2026 | HOLD | $12.87 | — / — | -3.5% | not yet | The current market regime and the stock's fundamentals do not support a BUY decision. |
| September 21, 2026 | HOLD | $13.07 | — / — | -2.4% | not yet | The stock is currently in a neutral market regime and the technicals are not strongly bullish. |
| September 18, 2026 | HOLD | $12.87 | — / — | -5.4% | not yet | Successful commercialization and market adoption of TUDRIQEV™. |
| September 11, 2026 | HOLD | $13.24 | — / — | +1.2% | +3.9% | The current market regime and the stock's fundamental and risk profile do not support a BUY recommendation. |
| August 14, 2026 | BUY | $15.19 | — / — | -1.3% | -12.4% | Post-earnings drift signal from scanner. |
| August 11, 2026 | SELL | $12.06 | — / — | +14.1% | +5.9% | FDA approval of Tudriqev for melanoma, a significant regulatory milestone. |
| August 10, 2026 | SELL | $12.06 | — / — | +7.0% | +8.1% | FDA approval of Tudriqev for melanoma, a significant regulatory milestone. |
| August 6, 2026 | BUY | $11.83 | — / — | +18.1% | +18.9% | Positive FDA advisory panel vote for RP1 in melanoma. |
| August 5, 2026 | HOLD | $11.92 | — / — | +28.8% | +35.1% | The stock is at a critical resistance level with mixed signals, requiring further price action confirmation. |
| August 4, 2026 | HOLD | $11.91 | — / — | +14.5% | +31.5% | The stock is in a neutral market and has conflicting signals from the technical and fundamental teams. |
| July 17, 2026 | HOLD | $9.52 | — / — | -5.2% | +46.3% | FDA agreement to resubmit BLA for melanoma drug. |
| July 16, 2026 | BUY | $9.68 | — / — | +9.9% | +59.6% | FDA decision on the BLA resubmission for the melanoma drug. |
| July 15, 2026 | BUY | $9.87 | — / — | +11.1% | +57.4% | FDA's acceptance of BLA resubmission for a melanoma drug. |
| July 14, 2026 | HOLD | $9.94 | — / — | +11.4% | +38.3% | FDA resubmission plans for melanoma drug RP1. |
| June 5, 2026 | BUY | $9.87 | — / — | -6.2% | +21.5% | The stock is experiencing post-earnings drift, but the fundamental and risk profiles are concerning. |
| June 4, 2026 | BUY | $9.98 | — / — | -12.7% | +16.2% | The stock is in a neutral market environment, and the fundamental analysis is strongly bearish, outweighing the bullish technicals. |
| June 3, 2026 | BUY | $8.87 | — / — | -15.1% | +16.0% | The stock is in a short-term consolidation phase following a significant gap up. |
| June 2, 2026 | HOLD | $9.00 | — / — | +4.2% | +26.5% | FDA agreement to prioritize RP1 resubmission for melanoma. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.